Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.68 |
| ▸ | MAPT | P10636 | 8/20 | 0.68 |
| ▸ | CTSB | P07858 | 1/20 | 0.55 |
| ▸ | AR | P10275 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 4/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | TNNI3 | P19429 | 2/20 | 0.50 |
| ▸ | TNNT2 | P45379 | 2/20 | 0.50 |
| ▸ | TNNC1 | P63316 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21031716 | 0.98 | ALDH1A1 (0.67) | ALDH1A1MAPTCTSBARL3MBTL1 | |
| SCHEMBL2892379 | 0.87 | MAPT (0.55) | ALDH1A1MAPTL3MBTL1CYP1A2CYP2C19 | |
| SCHEMBL8103840 | 0.83 | ALDH1A1 (0.70) | ALDH1A1MAPTCTSBARL3MBTL1 | |
| SCHEMBL21001112 | 0.81 | KDM4E (0.53) | ALDH1A1MAPTCTSBARL3MBTL1 | |
| SCHEMBL30168936 | 0.81 | KDM4E (0.53) | ALDH1A1MAPTCTSBARL3MBTL1 | |
| SCHEMBL19700166 | 0.81 | CTSB (0.55) | ALDH1A1MAPTCTSBARL3MBTL1 | |
| SCHEMBL25796770 | 0.80 | ALDH1A1 (0.67) | ALDH1A1MAPTCTSBARL3MBTL1 | |
| SCHEMBL8484094 | 0.77 | ALDH1A1 (0.62) | ALDH1A1MAPTCTSBARL3MBTL1 | |
| SCHEMBL19690428 | 0.76 | RAB9A (0.46) | ALDH1A1MAPTL3MBTL1CYP1A2CYP2C19 | |
| SCHEMBL19690296 | 0.76 | RAB9A (0.56) | ALDH1A1MAPTPOLBLMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957078-B1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | BAYER HEALTHCARE LLC (US) | 2013-08-28 | — | — | EP | disclosed |
| EP-1957078-B1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | BAYER HEALTHCARE LLC (US) | 2013-08-28 | — | — | EP | disclosed |
| US-8338594-B2 | Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase | BAYER HEALTHCARE LLC (US) | 2012-12-25 | — | — | US | disclosed |
| US-8338594-B2 | Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase | BAYER HEALTHCARE LLC (US) | 2012-12-25 | — | — | US | disclosed |
| US-20110021518-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | BAYER HEALTHCARE LLC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110021518-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | BAYER HEALTHCARE LLC. (US) | 2011-01-27 | — | — | US | disclosed |
| EP-1957078-A2 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | Bayer Healthcare, LLC (US) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007064932-A2 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | BAYER HEALTHCARE LLC. (US) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007064932-A2 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | BAYER HEALTHCARE LLC. (US) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021518-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | AURKC, AURKA, PLK1 | ALDH1A1 3546/4885MAPT 1008/4885CTSB 1747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.